Abstract:Non-nucleosides reverse transcriptase inhibitors (NNRTIs), specifically targeting the HIV-1 reverse transcriptase (RT), play a unique role in anti-AIDS agents due to their high antiviral potency, structural diversity, and low toxicity in antiretroviral combination therapies used to treat HIV. However, due to the emergence of new drug-resistant strains, the development of novel NNRTIs with adequate potency, improved resistance profiles and less toxicity is highly required. In this work, a novel virtual screening strategy combined with structure-based drug design was proposed to discover the potential inhibitors against drug-resistant HIV strains. Seven structure-variant RTs, ranging from the wild type to a hypothetical multi-mutant were regarded as target proteins to perform structure-based virtual screening. Totally 23 small molecules with good binding affinity were identified from the Traditional Chinese Medicine database (TCM) as potential NNRTIs candidates. Among these hits, (+)-Hinokinin has confirmed anti-HIV activity, and some hits are structurally identical with anti-HIV compounds. Almost all these hits are consistent with external experimental results. Molecular simulations analysis revealed that top 2 hits (Pallidisetin A and Pallidisetin B) bind stably and in high affinity to HIV-RT, which are ready to be experimental confirmed. These results suggested that the strategy we proposed is feasible, trustworthy and effective. Our finding might be helpful in the identification of novel NNRTIs against drug-resistant, and also provide a new clue for the discovery of HIV drugs in natural products.Communicated by Ramaswamy H. Sarma.

"Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets.

"Old Dogs with New Tricks": Exploiting Alternative Mechanisms of Action and New Drug Design Strategies for Clinically Validated HIV Targets.

Progress on AIDS drug targets and small molecule inhibitors

Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.

Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors

Update on Recent Developments in Small Molecular HIV-1 RNase H Inhibitors (2013-2016): Opportunities and Challenges

Novel strategies in rational design of anti-HIV agents:multitarget and multivalency ligands

Progress on HIV-1 RT inhibitors with novel mechanism of action

Discovery of Non-Peptide Small Molecular Cxcr4 Antagonists As Anti-Hiv Agents: Recent Advances and Future Opportunities

Synthetic approaches and application of clinically approved small-molecule Anti-HIV drugs: An update

Deciphering the enigmas of non‐nucleoside reverse transcriptase inhibitors (NNRTIs): A medicinal chemistry expedition towards combating HIV drug resistance

Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: a Patent Review (2005 – 2010)

Novel Drug Targets for Anti-Hiv-1 Therapy

[Research Progress of Dual Inhibitors Targeting HIV-1 Reverse Transcriptase and Integrase].

New strategy for identifying potential natural HIV-1 non-nucleoside reverse transcriptase inhibitors against drug-resistance: an in silico study

Recent Advances in Computer-aided Antiviral Drug Design Targeting HIV-1 Integrase and Reverse Transcriptase Associated Ribonuclease H

Targeting Protein-Protein Interactions: a Promising Avenue of Anti-Hiv Drug Discovery.

Recent Progress in Small Molecule CCR5 Antagonists As Potential HIV-1 Entry Inhibitors

The successes and failures of HIV drug discovery

Recent advances in the discovery and development of novel HIV-1 NNRTI platforms (Part II): 2009-2013 update

Recent Advances in the Discovery and Development of Novel HIV-1 NNRTI Platforms: 2006-2008 Update

&quot;Old Dogs with New Tricks&quot;: exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets.